Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2005-11-01
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S962000, C424S451000, C424S464000
Reexamination Certificate
active
06960613
ABSTRACT:
Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.
REFERENCES:
patent: 3467675 (1969-09-01), Peterson et al.
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4650884 (1987-03-01), Bogeso
patent: 4902710 (1990-02-01), Foster et al.
patent: 4943590 (1990-07-01), Boegesoe et al.
patent: 4962128 (1990-10-01), Doogan et al.
patent: 5114976 (1992-05-01), Norden
patent: 5296507 (1994-03-01), Tanaka et al.
patent: RE34712 (1994-08-01), Boegesoe et al.
patent: 5627196 (1997-05-01), Hibschman et al.
patent: 5648396 (1997-07-01), Young et al.
patent: 5788986 (1998-08-01), Dodman
patent: 5958429 (1999-09-01), Wong
patent: 5962514 (1999-10-01), Evenden et al.
patent: 6069177 (2000-05-01), Carlier et al.
patent: 6147072 (2000-11-01), Bymaster et al.
patent: 6159971 (2000-12-01), Berg et al.
patent: 6169105 (2001-01-01), Wong et al.
patent: 6184219 (2001-02-01), Evenden et al.
patent: 6333357 (2001-12-01), Eig
patent: 6469064 (2002-10-01), Druzgala
patent: 2002/0103249 (2002-08-01), Bogeso et al.
patent: 0 347 066 (1989-12-01), None
patent: 0474580 (1992-03-01), None
patent: 0714663 (1996-06-01), None
patent: 0759299 (1997-02-01), None
patent: 0 814 084 (1997-12-01), None
patent: WO-92/18005 (1992-10-01), None
patent: WO-93/09769 (1993-05-01), None
patent: WO-96/24353 (1996-08-01), None
patent: WO-99/14207 (1999-03-01), None
patent: WO-00/02551 (2000-01-01), None
patent: WO-00/03701 (2000-01-01), None
patent: WO-00/15219 (2000-03-01), None
patent: WO-00/15220 (2000-03-01), None
patent: WO-00/34263 (2000-06-01), None
patent: WO-01/03694 (2001-01-01), None
patent: WO-01/54681 (2001-08-01), None
Hytell, J., et al., “The pharmacological effect of citalopram resides in the (S) − (+)-enantiomer”, Journal of Neural Transmission, 1992, vol. 88, No. 2, pp. 157-160.
Lepola U., et al., “Citalopram in the Treatment of Social Phobia: A Report of Three Cases”, Pharmacopsychiatry, Sep. 1994, vol. 27, No. 5, pp. 186-188.
Bouwer, C., et al., “Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia”, Journal of Affective Disorders, Apr. 1998, vol. 49, No. 1, pp. 79-82.
Humble, M., et al., “Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders”, International Clinical Psychopharmacology, 1992, vol. 6, No. suppl 5, pp. 21-39.
Sanchez, Connie, et al., “Behaviorial profiles of SSRIs in animal models of depression, anxiety and aggression”, Psychopharmacology, 1997, vol. 129, pp. 197-205.
Sanchez, C., R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model, European Journal of Pharmacology, 464, 2003, pp. 155-158.
Montgomery, S. et al., Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model, Pharmacology & Toxicology, 2001, 88, 282-286.
Sanchez, C., Stress-induced vocalisation in adult animals: A valid model of anxiety?, European Journal of Pharmacology, 463 (2003) 133-143.
Burke, W., et al., Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients, J. Clin Psychiatry, 63:4, Apr. 2002.
Wade, A. e t al., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression i primary care, International Clinical Psychopharmacology 2002, vol. 17 No. 3.
Stahl, et al., J. Clin. Psychiatry 2003; 64: 1322-1327.
Poster, Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, Apr. 9-12, 2003, Juan-les-Pins, France, 1 page.
Kasper, Siegfried, et al., “Escitalopram is Efficacious and well Tolerated in Treatment of Social Anxiety Disorder”, ADAA National Conference, Mar. 21-24, 2002, 1 page.
Davidson, Jonathan, et al., “Escitalopram in the Treatment of Generalized Anxiety Disorder”, Presented at the 22nd National Conference of the Anxiety Disorder Association of America, Mar. 21-24, 2002, Austin, Texas, NR57, 1 page.
Stahl, Stephen, et al., “Escitalopram in the Treatment of Panic Disorder”, Presented at the 22nd National Conference of the Anxiety Disorders Association of America, Mar. 21-24, 2002, Austin, Texas, NR56, 1 page.
Lader, Malcolm, et al., “Efficacy and Tolerability of Escitalopram in 12- and 24-Week Treatment of Social Anxiety Disoder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study”, Depression and Anxiety, 19: 241-248 (2004).
Huffman, Jeff C., et al., “The Development of New Antidepressants: Focus on Duloxetine and Escitalopram”, Harv Rev Psychiatry, 11:30-36 (2003).
Waugh, John, et al., “Escitalopram, A review of its Use in the Management of Major Depressive and Anxiety Disorders”, CNS Drugs, 17 (5): 343-362 (2003).
Burke, William J., “Escitalopram”, Expert Opin. Investig. Drugs, 11(10): 1477-1486 (2002).
Farah, Andrew, “Therapeutic Advantages of Escitalopram in Depression and Anxiety Disorders”, Primary Psychiatry, 9(12): 30-35 (2002).
Willner, P., Psychopharmacology, 1997, 134, 319-329.
Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 18-25.
Nierenber, A.A and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9.
Sackelm, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17.
Montgomery, S.A., et al., “The antidepressant efficacy of citalopram”, International Clinical Psychopharmacology (1996), vol. 11, Supplement 1, pp. 29-33.
Bouchard, J.M., et al., “Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial”, Journal of Affective Disorders, vol. 46, pp. 51-58 (1997).
Hytell, J., Prog. Neuro-Psychopharmocol. & Biol. Psychiat., 1982, 6, 277-295.
Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486.
Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonice vocalization in adult male rats, Behav. Pharmacol. 1993; 4:267-277.
Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995).
A.F. Joubert et al., “Citalopram and Anxiety Disorders,” Rev. Contemp. Pharmacither 10: 79-131 (1999).
Ulla M. Lepola et al., “A Controlled Perspective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder,” J. CLin. Psychiatry 59, 10: 528-534 (1998).
H. Koponen et al., “Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study,” Acta Psychiatrica Scandinavica 96:343-346 (1997).
Dan J. Stein et al., “Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder,” Journal of Serotonin Research 1: 29-33 (1996).
Bigler, Allan et al., “Quantitative Struacture-activity Relationships in a Series of Selective 5-HT uptake inhibitors,” Eur. J. Med. Chem. 3:289-295 (1997).
Soraya Seedat et al., “Open Trial of Citalopram in adults with post-tramatic stress disorder,” International Journal of Neuropsychopharmacology 3: 135-140 (2000).
Ihoko Muraki et al., “Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat,” European Journal of Pharmacology 383:223-229 (1999).
Jennifer Y. Tan et al, “Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry,” Pharmacother
Hogg Sandra
Sanchez Connie
Darby & Darby
H. Lundbeck A/S
Krass Frederick
LandOfFree
Treatment of neurotic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurotic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurotic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486617